Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), Huge was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC).It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC.The results of clinical trials revealed the superiority of PD-1/programmed death li